Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients

NCT01738646 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Glioblastoma Multiforme
Malignant Glioma
Adult Brain Tumor

Interventions

DRUG: Vorinostat
DRUG: Bevacizumab

Sponsor

Duke University

Collaborators

[object Object]
[object Object]